Palliation of malignant dysphagia in esophageal cancer: A literature-based review

Milind Javle, Sikander Ailawadhi, Gary Y. Yang, Chukwumere E. Nwogu, Michael D. Schiff, Hector R. Nava

Research output: Contribution to journalReview article

61 Citations (Scopus)

Abstract

Esophageal cancer is a lethal malignancy and adenocarcinoma of the esophagus is increasing in incidence. Most patients present with locally advanced, unresectable or metastatic disease.The 5-year survival rate of patients with esophageal cancer is < 20%. Dysphagia is the most common presenting symptom of this disease and leads to nutritional compromise, pain, and deterioration of quality of life. Palliation is an important goal of esophageal cancer therapy. Severity is commonly measured using a dysphagia grade, and dysphagia is an integral component of quality-of-life instruments, such as FACT-E and EORTC-OES 24. Investigation of dysphagia includes radiographic studies such as barium or Gastrografin swallow, esophagogastroduodenoscopy, endoscopic ultrasonography, and other staging studies for esophageal cancer. Current management options for the palliation of dysphagia include esophageal dilatation, intraluminal stents, Nd:YAG laser therapy, photodynamic therapy, argon laser, systemic chemotherapy, external beam radiation therapy, brachytherapy, and combined chemoradiation therapy. The clinical situation, local expertise, and cost effectiveness play an important role in choosing the appropriate treatment modality. The benefits and disadvantages of these approaches along with a concise review of the literature are presented.

Original languageEnglish (US)
JournalJournal of Supportive Oncology
Volume4
Issue number8
StatePublished - Sep 2006
Externally publishedYes

Fingerprint

Esophageal Neoplasms
Deglutition Disorders
Quality of Life
Diatrizoate Meglumine
Digestive System Endoscopy
Endosonography
Argon
Solid-State Lasers
Brachytherapy
Photochemotherapy
Laser Therapy
Barium
Deglutition
Cost-Benefit Analysis
Stents
Dilatation
Lasers
Radiotherapy
Therapeutics
Survival Rate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Javle, M., Ailawadhi, S., Yang, G. Y., Nwogu, C. E., Schiff, M. D., & Nava, H. R. (2006). Palliation of malignant dysphagia in esophageal cancer: A literature-based review. Journal of Supportive Oncology, 4(8).

Palliation of malignant dysphagia in esophageal cancer : A literature-based review. / Javle, Milind; Ailawadhi, Sikander; Yang, Gary Y.; Nwogu, Chukwumere E.; Schiff, Michael D.; Nava, Hector R.

In: Journal of Supportive Oncology, Vol. 4, No. 8, 09.2006.

Research output: Contribution to journalReview article

Javle, Milind ; Ailawadhi, Sikander ; Yang, Gary Y. ; Nwogu, Chukwumere E. ; Schiff, Michael D. ; Nava, Hector R. / Palliation of malignant dysphagia in esophageal cancer : A literature-based review. In: Journal of Supportive Oncology. 2006 ; Vol. 4, No. 8.
@article{13c105af32334182b934a2970b4a1dd6,
title = "Palliation of malignant dysphagia in esophageal cancer: A literature-based review",
abstract = "Esophageal cancer is a lethal malignancy and adenocarcinoma of the esophagus is increasing in incidence. Most patients present with locally advanced, unresectable or metastatic disease.The 5-year survival rate of patients with esophageal cancer is < 20{\%}. Dysphagia is the most common presenting symptom of this disease and leads to nutritional compromise, pain, and deterioration of quality of life. Palliation is an important goal of esophageal cancer therapy. Severity is commonly measured using a dysphagia grade, and dysphagia is an integral component of quality-of-life instruments, such as FACT-E and EORTC-OES 24. Investigation of dysphagia includes radiographic studies such as barium or Gastrografin swallow, esophagogastroduodenoscopy, endoscopic ultrasonography, and other staging studies for esophageal cancer. Current management options for the palliation of dysphagia include esophageal dilatation, intraluminal stents, Nd:YAG laser therapy, photodynamic therapy, argon laser, systemic chemotherapy, external beam radiation therapy, brachytherapy, and combined chemoradiation therapy. The clinical situation, local expertise, and cost effectiveness play an important role in choosing the appropriate treatment modality. The benefits and disadvantages of these approaches along with a concise review of the literature are presented.",
author = "Milind Javle and Sikander Ailawadhi and Yang, {Gary Y.} and Nwogu, {Chukwumere E.} and Schiff, {Michael D.} and Nava, {Hector R.}",
year = "2006",
month = "9",
language = "English (US)",
volume = "4",
journal = "Journal of Supportive Oncology",
issn = "1544-6794",
publisher = "Biolink Communications, Inc.",
number = "8",

}

TY - JOUR

T1 - Palliation of malignant dysphagia in esophageal cancer

T2 - A literature-based review

AU - Javle, Milind

AU - Ailawadhi, Sikander

AU - Yang, Gary Y.

AU - Nwogu, Chukwumere E.

AU - Schiff, Michael D.

AU - Nava, Hector R.

PY - 2006/9

Y1 - 2006/9

N2 - Esophageal cancer is a lethal malignancy and adenocarcinoma of the esophagus is increasing in incidence. Most patients present with locally advanced, unresectable or metastatic disease.The 5-year survival rate of patients with esophageal cancer is < 20%. Dysphagia is the most common presenting symptom of this disease and leads to nutritional compromise, pain, and deterioration of quality of life. Palliation is an important goal of esophageal cancer therapy. Severity is commonly measured using a dysphagia grade, and dysphagia is an integral component of quality-of-life instruments, such as FACT-E and EORTC-OES 24. Investigation of dysphagia includes radiographic studies such as barium or Gastrografin swallow, esophagogastroduodenoscopy, endoscopic ultrasonography, and other staging studies for esophageal cancer. Current management options for the palliation of dysphagia include esophageal dilatation, intraluminal stents, Nd:YAG laser therapy, photodynamic therapy, argon laser, systemic chemotherapy, external beam radiation therapy, brachytherapy, and combined chemoradiation therapy. The clinical situation, local expertise, and cost effectiveness play an important role in choosing the appropriate treatment modality. The benefits and disadvantages of these approaches along with a concise review of the literature are presented.

AB - Esophageal cancer is a lethal malignancy and adenocarcinoma of the esophagus is increasing in incidence. Most patients present with locally advanced, unresectable or metastatic disease.The 5-year survival rate of patients with esophageal cancer is < 20%. Dysphagia is the most common presenting symptom of this disease and leads to nutritional compromise, pain, and deterioration of quality of life. Palliation is an important goal of esophageal cancer therapy. Severity is commonly measured using a dysphagia grade, and dysphagia is an integral component of quality-of-life instruments, such as FACT-E and EORTC-OES 24. Investigation of dysphagia includes radiographic studies such as barium or Gastrografin swallow, esophagogastroduodenoscopy, endoscopic ultrasonography, and other staging studies for esophageal cancer. Current management options for the palliation of dysphagia include esophageal dilatation, intraluminal stents, Nd:YAG laser therapy, photodynamic therapy, argon laser, systemic chemotherapy, external beam radiation therapy, brachytherapy, and combined chemoradiation therapy. The clinical situation, local expertise, and cost effectiveness play an important role in choosing the appropriate treatment modality. The benefits and disadvantages of these approaches along with a concise review of the literature are presented.

UR - http://www.scopus.com/inward/record.url?scp=33749618667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749618667&partnerID=8YFLogxK

M3 - Review article

C2 - 17004508

AN - SCOPUS:33749618667

VL - 4

JO - Journal of Supportive Oncology

JF - Journal of Supportive Oncology

SN - 1544-6794

IS - 8

ER -